• Who We Are
    • Letter from the CEO
    • About Us
    • Our Team
  • Science
  • Pipeline
    • Pipeline Overview
    • NVD-003
    • NVD-X3
  • Patients
  • Investors
  • Contact
  • Careers
What's New
  • Home
  • Who We Are
    • Letter from the CEO
    • About Us
    • Our Team
  • Science
  • Pipeline
    • Pipeline Overview
    • NVD-003
    • NVD-X3
  • Patients
  • Investors
  • What’s New
  • Contact
  • Careers

Résultats encourageants pour le réducteur de fractures de Novadip

by Novadip | Dec 8, 2022 | Featured News

Novadip annonce des résultats positifs de l’essai clinique de son traitement expérimental de guérison de fractures osseuses.

Novadip Biosciences SA Announces Positive Results from Phase 1/2 Clinical Trial in Patients with Severe Bone Non-Union of the Lower Limb Following Trauma

by Novadip | Dec 8, 2022 | Press Releases

MONT SAINT-GUIBERT, Belgium–(BUSINESS WIRE)–Novadip Biosciences SA (“Novadip” or “the Company”), a clinical-stage biopharmaceutical company developing a new class of regenerative tissue products to accelerate healing of large bone defects and injuries in a...

Innovation in Tissue Regeneration Improves Spine Fusions and Fracture Repairs

by Novadip | Nov 21, 2022 | Featured News

Novadip Biosciences recently received an infusion of €40 million (~USD $40 million) in investments, increasing its total funding to €88 million. The Belgium-based company will use the capital to develop a new class of adipose-derived stem cell (ASC) tissue...

Novadip Biosciences Raises Funds to Support Regenerative Tissue Products

by Novadip | Nov 7, 2022 | Featured News

Novadip Biosciences raised an additional €40 million (~USD $40 million) in a Series B equity round and non-dilutive funding. This brings the company’s total funding to €88 million, to date.

Biotech Funding Roundup: HI-Bio’s Haul, Concerto’s Cash, Lusaris’s Launch & More

by Novadip | Nov 6, 2022 | Featured News

Tissue regeneration biotech Novadip Biosciences raised €40 million. The cash will go toward two clinical-stage programs: an allogeneic bone union therapeutic called NVD-X3 and NVD-003, an autologous bone engraftment product. The cash breaks down to €24 million in...
« Older Entries
Next Entries »

Stay Updated by Joining Our Email List

Success!

Subscribe

NOVADIP

Novadip is advancing the standard of care
in bone and tissue regenerative medicine

info@novadip.com

+32 (10) 779 220

Navigation

Who We Are

Our Science

Our Pipeline

Patients

Investors

What’s New

Get In Touch

Contact

Careers

Legal

Privacy Policy

Cookie Policy

Information Notice

Proposed Expanded Access Policy

©2022 NOVADIP. All Rights Reserved.

  • Follow